抗感染治疗对接受华法林治疗的患者的影响
Linlin Fu1, Huimin Yao2, Wei Xu2
1Department of Pharmacy, Nanjing Drum Tower Hospital, Basic Medicine and Clinical Pharmacy College, China Pharmaceutical University, Nanjing 210008, China.
Journal of infection in developing countries
|January 20, 2025
概括
某些抗生素显著增加了华法林的作用,提高了国际正常化比率 (INR) 值. 昆类药物,硫胺类药物和抗真菌药物在与华法林结合时最明显地影响INR.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
- 传染性疾病 传染性疾病
背景情况:
- 华法林和抗生素的同时使用在临床环境中很常见.
- 各种抗生素对华法林抗凝剂功效的确切影响尚不清楚.
- 这种不确定性使得两种药物患者的临床决策更加复杂.
研究的目的:
- 研究不同类型的抗生素如何影响接受华法林治疗的患者的国际正常化比率 (INR).
- 识别导致INR值发生显著变化的特定抗生素类型.
主要方法:
- 进行了一项回顾性队列研究,涉及623名住院患者.
- 患者在2013年至2022年期间同时接受华法林和抗生素治疗.
- 患者按抗生素类型 (8类) 分组,并分析了INR的变化.
主要成果:
- 在华法林患者中,抗生素使用通常会增加INR值.
- 诺,硫胺和抗真菌剂显示出最显著的INR升高.
- β-乳类药物,糖类,氧利丁,类药物和卡巴类药物对INR的影响不那么明显.
结论:
- 与抗生素同时服用华法林会导致INR值增加.
- 诺,硫胺和抗真菌剂与最大的INR升高有关.
- 对这些相互作用的认识对于安全的华法林管理至关重要.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
606
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
606
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
464
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
464
Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Factors Affecting Protein-Drug Binding: Drug Interactions
99
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
99


